PRMT5 and pachyonychia congenita: EZP015556, an inhibitor of PRMT5, is found to be effective in MTAP (a gene commonly lost in PC) negative tumors in preclinical experiments, and now there are a few clinical trials on this inhibitor ongoing (NCT03573310, NCT02783300, and NCT03614728) (73).